Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD
Conditions
Group 3 Pulmonary Hypertension
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hualien Tzu Chi Hospital, Hualien City, Taiwan
Contact: Principal Investigator (Wei-Hsin Liu, M.D.)Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan
Contact: Principal Investigator (Kun-Chang Lin, MD)Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Contact: Principal Investigator (Chun-Yuan Chu, M.D.)Taichung Veterans General Hospital, Taichung, Taiwan
Contact: Principal Investigator (Pin-Kuei Fu, M.D.)National Cheng Kung University Hospital, Tainan, Taiwan
Contact: Principal Investigator (Chih-Hsin Hsu, MD)National Taiwan University Hospital, Taipei, Taiwan
Contact: Principal Investigator (Ping-Hung Kuo, M.D.)MacKay Memorial Hospital, Taipei, Taiwan
Contact: Principal Investigator (Yih-Jer Wu, MD)Taipei Veterans General Hospital, Taipei, Taiwan
Contact: Principal Investigator (Shih-Hsien Sung, M.D.)Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan
Contact: Principal Investigator (Wan-Jing Ho, M.D.)
Study leads
Bassem Elmankabadi, MD
Study Director
Foresee Pharmaceuticals